Kairos Pharma Prices $6.2 Million Initial Public Offering
Kairos Pharma, Ltd. (KAPA)
Company Research
Source: GlobeNewswire
LOS ANGELES, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (“Kairos Pharma” or the “Company”), a clinical stage biopharmaceutical company developing cancer therapeutics designed to reverse cancer drug resistance and immune suppression, announces the pricing of its initial public offering of 1,550,000 shares of common stock at a public offering price of $4.00 per share. In addition, the Company has granted to the underwriters a 45-day option to purchase up to an additional 232,500 shares of common stock at the public offering price of $4.00 per share, less underwriting discounts and commissions, to cover over-allotments, if any. The Company’s common stock has been approved for listing on the NYSE American LLC (“NYSE American”). Trading is expected to begin on September 16, 2024 under the symbol “KAPA.” The gross proceeds from the offering, before deducting underwriting fees and other offering expenses payable by the Company, are expected to be $6.2 million. The offering i
Show less
Read more
Impact Snapshot
Event Time:
KAPA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KAPA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KAPA alerts
High impacting Kairos Pharma, Ltd. news events
Weekly update
A roundup of the hottest topics
KAPA
News
- Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients [Yahoo! Finance]Yahoo! Finance
- Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer PatientsGlobeNewswire
- Kairos Pharma Closing of $6.2 Million Initial Public OfferingGlobeNewswire
- Kairos Pharma Prices $6.2 Million Initial Public Offering [Yahoo! Finance]Yahoo! Finance
KAPA
Sec Filings
- 10/4/24 - Form 8-K
- 9/27/24 - Form S-8
- 9/27/24 - Form 8-K
- KAPA's page on the SEC website